Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263895 | 0.83 | MGAM (0.51) | MEN1KMT2ASCN10ASCN9ALRRK2 | |
| SCHEMBL269263 | 0.81 | MEN1 (0.44) | MEN1KMT2ASCN10ASCN9ALRRK2 | |
| SCHEMBL28428705 | 0.81 | CYP1A2 (0.50) | MEN1KMT2ASCN9A | |
| SCHEMBL12520183 | 0.80 | HSD17B14 (0.51) | MEN1KMT2A | |
| SCHEMBL27887111 | 0.78 | BACE1 (0.46) | — | |
| SCHEMBL26803625 | 0.78 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL25497861 | 0.78 | MEN1 (0.47) | MEN1KMT2ASCN10ASCN9A | |
| SCHEMBL25901172 | 0.75 | MEN1 (0.45) | MEN1KMT2ASCN10ASCN9A | |
| SCHEMBL284008 | 0.74 | ALDH1A1 (0.47) | MEN1KMT2AHSP90AA1HSP90AB1ACHE | |
| SCHEMBL8237398 | 0.74 | MGAM (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | MEN1 4051/4885KMT2A 4132/4885SCN10A 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.